<DOC>
	<DOCNO>NCT02884726</DOCNO>
	<brief_summary>The purpose study assess safety tolerability Mesothelin-ADC subject advance and/or metastatic solid tumor .</brief_summary>
	<brief_title>Phase 1 Study Mesothelin-ADC</brief_title>
	<detailed_description />
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Must histological confirmation advance and/or metastatic solid tumor expect express mesothelin Must receive either progress intolerant standard treatment regimen advance metastatic setting , therapy exists Must measurable tumor per Response Evaluation Criteria Solid Tumors ( RECIST ) modify RECIST malignant pleural mesothelioma Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Cancer metastasis brain Uncontrolled significant cardiovascular disease Moderate eye disorder Moderate peripheral neuropathy Known past active hepatitis B C infection Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>